Diabytes
Novartis gets USFDA warning letter for two plants in India
Sandoz, the generic drug arm of Swiss drug major Novartis, has received a warning letter from the US health regulator for violations of current good manufacturing practice (cGMP) norms at its two plants in Western India.
Trending Photos
10- 12
- 8
- 13
New Delhi: Sandoz, the generic drug arm of Swiss drug major Novartis, has received a warning letter from the US health regulator for violations of current good manufacturing practice (cGMP) norms at its two plants in Western India.
"On October 22, 2015, the US Food and Drug Administration (USFDA) issued a warning letter to our Sandoz Division concerning their Indian sites in Kalwe and Turbhe," Novartis AG said in its quarterly result statement.
Both Turbhe and Kalwe fall in Maharashtra.
The warning letter observations follow USFDA inspection at both sites in August 2014 and are related to deficiencies in current good manufacturing practice (cGMP) for finished pharmaceuticals, it added.
"The warning letter does not contain any new issues versus the 483 observations issued following the inspection in August 2014, which Sandoz has been addressing since then," the company said.
Sandoz will continue to work closely with the FDA to ensure all observations are resolved to the agency's full satisfaction, it added.
No supply disruptions are expected, the company noted.
At Turbhe, Sandoz mainly produces active pharmaceutical ingredients. In Kalwe oral solid dosages or tablets are produced.
Live Tv
 "Modi gave a big hint in nomination from Varanasi")
 "Who is responsible for the hoarding accident in Ghatkopar")
 "Why was America embarrassed by India's Chabahar deal")
 "DNA: India's first digital beggar Raju dies")
 "DNA test of your utensils")
 "DNA: How to know if gold is real?")
 "DNA: What is the Fatehpur Sikri Masjid-Mandir controversy?")
 "DNA: Lok Sabha elections...Is there a game in voting?")
 "DNA: Rahul Gandhi-Akhilesh Yadav Holds Join Rally In Kannauj")
 "DNA: Analysis of Supreme Court's decision on Kejriwal")
